Digene licenses cervical cancer marker:
This article was originally published in Clinica
Molecular diagnostics company Digene has obtained worldwide rights to a genetic marker linked to cervical cancer. The p53arg gene, which the Beltsville, Maryland-based company licensed from McGill University in Montreal, Canada and the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy, has been shown to predict cancers related to the human papillomavirus (HPV), of which cervical cancer is one. Digene's lead product is a DNA test for the HPV virus and is used as an adjunct to Pap smear testing in the US. A test for the p53arg gene could make HPV testing more effective for earlier cancer prognosis, said Digene.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.